Improvement of specific detection of circulating tumor cells using combined CD45 staining and fluorescence in situ hybridization

Clinica Chimica Acta

Volumn 433, Issue , 2014, Pages 69-75

  Ning, Ning ^a,b   Zhan, Ting ^a   Zhang, Yujuan ^a   Chen, Qian ^a   Feng, Fengzhi ^a   Yang, Zhuo ^a   Liu, Zhongjuan ^a   Xu, Danfei ^a   Wang, Fei ^a   Guo, Ye ^a   Xing, Jia ^a   Guan, Yuanyuan ^a   Cui, Wei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b HARBIN UNIVERSITY   (China)

Author keywords

CD45 FISH; CTCs; ICC; Lung cancer; Ovarian tumor

Indexed keywords

CD45 ANTIGEN;

ANTIGEN DETECTION; ARTICLE; BLOOD LEVEL; CELL ASSAY; CENTROMERE; CHROMOSOME 8; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EPITHELIUM CELL; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; INTERMETHOD COMPARISON; LUNG CANCER; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; OVARY CANCER; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; CELL SEPARATION; FEMALE; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; METABOLISM; OVARY TUMOR; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; TUMOR EMBOLISM;

ANTIGENS, CD45; CELL SEPARATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; OVARIAN NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 84896458143     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.02.019     Document Type: Article

References (37)

1. Mehlen P., Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer 2006, 6:449-458.
2. Chaffer C.L., Weinberg R.A. A perspective on cancer cell metastasis. Science 2011, 331:1559-1564.
3. Cristofanilli M., Budd G.T., Ellis M.J., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-791.
4. Cohen S.J., Punt C.J., Iannotti N., et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:3213-3221.
5. de Bono J.S., Scher H.I., Montgomery R.B., et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008, 14:6302-6309.
6. Uenosono Y., Arigami T., Kozono T., et al. Clinical significance of circulating tumor cells in peripheral blood from patients with gastric cancer. Cancer 2013, 119:3984-3991.
7. Mostert B., Sleijfer S., Foekens J.A., Gratama J.W. Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev 2009, 35:463-474.
8. Mocellin S., Keilholz U., Rossi C.R., Nitti D. Circulating tumor cells: the 'leukemic phase' of solid cancers. Trends Mol Med 2006, 12:130-139.
9. Nagrath S., Sequist L.V., Maheswaran S., et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007, 450:1235-1239.
10. Konigsberg R., Gneist M., Jahn-Kuch D., et al. Circulating tumor cells in metastatic colorectal cancer: efficacy and feasibility of different enrichment methods. Cancer Lett 2010, 293:117-123.
11. Lara O., Tong X., Zborowski M., Chalmers J.J. Enrichment of rare cancer cells through depletion of normal cells using density and flow-through, immunomagnetic cell separation. Exp Hematol 2004, 32:891-904.
12. Liu Y., Liu Q., Wang T., et al. Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker. BMC Cancer 2013, 13:202.
13. Muller V., Riethdorf S., Rack B., et al. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Res 2012, 14:R118.
14. Armstrong A.J., Marengo M.S., Oltean S., et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res 2011, 9:997-1007.
15. Joosse S.A., Hannemann J., Spotter J., et al. Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells. Clin Cancer Res 2012, 18:993-1003.
16. Zhang Z.Y., Ge H.Y. Micrometastasis in gastric cancer. Cancer Lett 2013, 336:34-45.
17. Tanaka F., Yoneda K., Kondo N., et al. Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res 2009, 15:6980-6986.
18. Sergeant G., van Eijsden R., Roskams T., Van Duppen V., Topal B. Pancreatic cancer circulating tumour cells express a cell motility gene signature that predicts survival after surgery. BMC Cancer 2012, 12:527.
19. Chen Q., Ge F., Cui W., et al. Lung cancer circulating tumor cells isolated by the EpCAM-independent enrichment strategy correlate with cytokeratin 19-derived CYFRA21-1 and pathological staging. Clin Chim Acta 2013, 419:57-61.
20. Wu C., Hao H., Li L., et al. Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J Thorac Oncol 2009, 4:30-36.
21. Liu Z., Fusi A., Klopocki E., et al. Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients. J Transl Med 2011, 9:70.
22. Dawood S., Broglio K., Valero V., et al. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?. Cancer 2008, 113:2422-2430.
23. Li J., Shi S.B., Shi W.L., et al. LUNX mRNA-positive cells at different time points predict prognosis in patients with surgically resected nonsmall cell lung cancer. Transl Res 2014, 163:27-35.
24. Vona G., Sabile A., Louha M., et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol 2000, 156:57-63.
25. Meng S., Tripathy D., Frenkel E.P., et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004, 10:8152-8162.
26. Meng S., Tripathy D., Shete S., et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 2004, 101:9393-9398.
27. Fehm T., Sagalowsky A., Clifford E., et al. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res 2002, 8:2073-2084.
28. Yu M., Stott S., Toner M., Maheswaran S., Haber D.A. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol 2011, 192:373-382.
29. Mostert B., Kraan J., Sieuwerts A.M., et al. CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes. Cancer Lett 2012, 319:49-55.
30. Krishnamurthy S., Bischoff F., Ann Mayer J., et al. Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer. Cancer Med 2013, 2:226-233.
31. Pailler E., Adam J., Barthelemy A., et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol 2013, 31:2273-2281.
32. Fiegl M., Massoner A., Haun M., et al. Sensitive detection of tumour cells in effusions by combining cytology and fluorescence in situ hybridisation (FISH). Br J Cancer 2004, 91:558-563.
33. Ntouroupi T.G., Ashraf S.Q., McGregor S.B., et al. Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope. Br J Cancer 2008, 99:789-795.
34. Eastmond D.A., Schuler M., Rupa D.S. Advantages and limitations of using fluorescence in situ hybridization for the detection of aneuploidy in interphase human cells. Mutat Res 1995, 348:153-162.
35. Liu Y.Z., Wang Z., Fang L.L., et al. A potential probe set of fluorescence in situ hybridization for detection of lung cancer in bronchial brushing specimens. J Cancer Res Clin Oncol 2012, 138:1541-1549.
36. Yap T.A., Gerlinger M., Futreal P.A., Pusztai L., Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012, 4:127ps10.
37. Lu G., Muddasani R., Orlowski R.Z., et al. Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms. Arch Pathol Lab Med 2013, 137:625-631.